Our Manifesto
Our world is facing a mental health pandemic, with more than 1/8th of the global population suffering from a clinical indication.
Based on cutting-edge scientific research, rigorous case studies from various organizations, and our own beneficial experiences, we believe microdosing is a beneficial tool: both to better the well and to offer relief to those on traditional psychotropic medications.
Better Mental Health
Microdosing psychedelics has made a profound impact on countless individuals. Yet, limited research exists on the benefits of low-dose psychedelic use due to regulatory challenges and the novelty of such an approach. Almost all current psychedelic policy focuses on psychedelic-assisted psychotherapy using consciousness-altering doses.
Scientific Research
Policies around psychedelic legalization do not differentiate based on dosage, which is a major oversight. Microdoses require a different context due to their sub-perceptual nature. For that reason, the practice of microdosing requires unique regulatory policies to accurately reflect the different ways in which it is used. By forming a policy around microdosing, we intend to increase accessibility to the benefits of intentional psychedelic use.
Regulatory Reform
Each member of this collective has either been personally positively impacted by or supports broader access to the practice of microdosing psilocybin mushrooms with a structured supplement protocol and a clear intention for optimal well-being.
Representative
The Microdosing Collective wants to create momentum around changes to state and federal policy to support the legalization of microdosing, starting with psilocybin. We recognize that microdosing supplements are already being sold in many jurisdictions worldwide; and yet, the majority of commerce is unregulated and black market. We believe every human, if they wish, should be able to access microdosing medicine in a trustworthy and safe manner, with vetted and lab-tested products.
Legalization, Access, & Safety
Our community is one of diverse backgrounds and various walks of life, all of whom bring personal anecdotes as to the benefits of microdosing and serve as ambassadors for education and advocates for legalization. Through our organization we will seek to expand access to those who may benefit from its use, welcome those from cultures for whom microdosing has been both a sacrament and a medicine, and seek to positively impact each community we touch.
Community
Board
Alli Schaper
Alli Schaper is the CEO & Co-Founder of Into The Multiverse, an education-first ecosystem for all things fungi. Her mission is to rebrand functional mushrooms and encourage collaboration amongst the psychedelics industry. Alli's team created the world's first functional mushroom marketplace, The Multiverse alongside SuperMush, their in-house CPG brand. Alli is passionate about serving as an ally in bringing the future of psychedelics and microdosing to the mainstream wellness conversation.
Paul Austin
Paul F. Austin is an entrepreneur, psychedelic facilitator, and microdosing expert. He has founded two companies in the emerging psychedelic space: Third Wave and Synthesis. Because of his pioneering work at the intersection of psychedelic use, personal transformation, and professional success, Paul has been featured in the BBC, Forbes, and Rolling Stone. Paul sees psychedelic use as a skill, one continuously refined through intentional use, mentorship, and courageous exploration.
Josh Kappel
Josh Kappel is a founding partner of Vicente Sederberg with a practice focused on helping entrepreneurs and visionaries build human-centric and regenerative companies in the cannabis and psychedelic industries. With a passion for policy, Josh also loves helping advocates draft legislation and build sustaining vehicles that will forever influence these emerging industries.
Advisors
Courtney Barnes
Courtney is a devoted social justice attorney and leading trailblazer in drug policy reform, specializing in advising clients on regulatory compliance and risk management in highly regulated, emerging industries. She also serves as Policy Advisor for Decriminalize Nature, General Counsel for the Society for Psychedelic Outreach, Reform, and Education (SPORE), and Advisory Board Member of Heroic Hearts Project, Inc. She was a lead drafter of Denver’s Psilocybin Decriminalization Initiative (I-301) in 2018, and has unparalleled experience implementing state and local policy reform relating to the decriminalization of psychedelics and establishment of cannabis regulatory regimes.
Evan Lewis
Dr. Evan Lewis is a Neurologist and Clinical Neurophysiologist with expertise in pediatric neurology and epilepsy.
He is an Assistant Professor with the Department of Pediatrics at the Hospital for Sick Children and the University of Toronto. Dr. Lewis is the founder and medical director of the Neurology Centre of Toronto (NCT) and VP
of Psychedelic Neurology at Numinus –
a Canadian company focused on psychedelic research and
therapeutics. He joined the Numinus team in September 2021 with an intention to explore the utility of
psychedelics in the field of neurology.
Ian Benouis
Ian Benouis, JD, is the Founder of Entheo Law and his law firm has helped create over 20 entheogenic churches. He is a West Point graduate, former Blackhawk helicopter pilot, former US Army officer and combat veteran who participated in Operation Just Cause in the Republic of Panama the biggest operation in history directed towards the War on Drugs. He has been healing himself for over 25 years with natural earth medicines, a spiritual practice, and as a student and practitioner of ethnobotany. He has organized and participated in numerous trips with veterans to Mexico, Peru and other locations for ethnobotanical healing. His work has been captured in documentaries including From Shock to Awe and Soldiers of the Vine.
Ivan Casselman
Dr. Ivan Casselman is an experienced psychedelic researcher, writer, and business developer with over 20 years of experience in the psychedelic industry. He is the Chief Psychedelic Officer and Founder of HavnLife, a psychedelic company focused on exploring psilocybe spp mushrooms to empower human potential using evidence-informed research to unlock human performance and empower people to achieve their full potential. Dr. Casselman's experience in the development and authentication of herbal formulations provides him with unique insight into the production, product development and marketing positioning across various commercial applications.
John Downs
John Downs is an entrepreneur, investor, and advisor within the cannabis and psychedelic industries, and a peak performance and mindset coach specializing in integration and microdosing. He helps entrepreneurs, founders, executives, and creative high-achievers transform and increase performance, ease suffering, and create lasting fulfillment by embodying their true purpose. He discovered plant medicine in 2015 and began his own personal healing journey incorporating psychotherapy, men’s work, microdosing, embodiment practices, and the deep study of philosophy, archetypes, and the neurobiology of optimal states of consciousness (“Flow”).
Stephanie Karzon
Stephanie Karzon is a clinical pharmacologist with an established and evolving interest in neurology and psychedelics, as well as extensive career experience in business development and operations in the med/biotech industry. Stephanie is currently a scientific advisor for a number of projects, notably for the Neurology Centre of TO by Numinus where she is collaborating on research projects. In 2022, she co-created Mt Mushmore, Higher Elevations, an educational and social initiative. The objective of this monthly meetup is to encourage the growing conversation around mushrooms (both functional and psychedelic) and to provide education, opportunities, and connection for the curious, as well as for those in the industry.
Stories, education, and activism to promote a new public-policy paradigm with microdosing for optimal human happiness.
Statistics
10+
Clinical studies currently underway
500K+
Microdosers in the world today
96.7%
Of people find some benefit from microdosing
7
States currently considering policy around psychedelics
Our Partners
-01.png)
.png)